Literature DB >> 23898087

Primary central nervous system lymphoma in the elderly: the Cleveland clinic experience.

Hao Xie1, Saurabh Dahiya, Erin S Murphy, Samuel T Chao, John H Suh, Glen H J Stevens, David M Peereboom, Manmeet S Ahluwalia.   

Abstract

BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a type of extranodal non-Hodgkin lymphoma that involves only the central nervous system. Untreated PCNSL in the elderly has a rapidly fatal course. PATIENTS AND METHODS: In this retrospective study, we evaluated the demographics, management, and outcomes of patients over 60 years of age with PCNSL at our institution.
RESULTS: A total of 54 patients with a median age of 67 years were included in the analysis. The initial treatment regimens included whole-brain radiation therapy (WBRT), chemotherapy with or without consolidation WBRT. The median progression-free survival (PFS) was 8.0 months (95% confidence interval CI=2.7-22 months) and the median overall survival (OS) was 38 months (95% CI=18-65 months). On multivariable analysis, age younger than 70 years and Karnofsky Performance Status (KPS) no less than 70 were favorable prognostic factors for both OS and PFS.
CONCLUSION: Aggressive treatment strategies for elderly patients with PCNSL with good performance status can lead to improved outcomes in this patient population.

Entities:  

Keywords:  Lymphoma; chemotherapy; elderly; performance status; radiation

Mesh:

Year:  2013        PMID: 23898087

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Pilot study of gamma-knife surgery-incorporated systemic chemotherapy omitting whole brain radiotherapy for the treatment of elderly primary central nervous system lymphoma patients with poor prognostic scores.

Authors:  Joon Cho; Jihye Kim; Hui Jin Ryu; Hong Gee Roh; Hyun Woo Chung; Young-Cho Koh; Mark Hong Lee; Yoon-Ho Ko; Sung-Yong Kim
Journal:  Med Oncol       Date:  2014-02-05       Impact factor: 3.064

2.  Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a cost-effectiveness analysis.

Authors:  A Prica; K Chan; M Cheung
Journal:  Neuro Oncol       Date:  2014-05-05       Impact factor: 12.300

3.  The Real-World status and risk factors for a poor prognosis in elderly patients with primary central nervous system malignant lymphomas: a multicenter, retrospective cohort study of the Tohoku Brain Tumor Study Group.

Authors:  Kenichiro Asano; Yoji Yamashita; Takahiro Ono; Manabu Natsumeda; Takaaki Beppu; Kenichiro Matsuda; Masahiro Ichikawa; Masayuki Kanamori; Masashi Matsuzaka; Akira Kurose; Kiyoshi Saito; Yukihiko Sonoda; Kuniaki Ogasawara; Yukihiko Fujii; Hiroaki Shimizu; Hiroki Ohkuma; Chifumi Kitanaka; Takamasa Kayama; Teiji Tominaga
Journal:  Int J Clin Oncol       Date:  2021-10-12       Impact factor: 3.402

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.